Rigel Pharmaceuticals Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Rigel Pharmaceuticals Inc 公司

Rigel Pharmaceuticals, Inc. 是一家生物技術公司。該公司致力於開發和提供新型療法，以顯著改善血液病和癌症患者的生活。該公司專注於解決對疾病機制至關重要的信號通路的產品。其首款產品是 TAVALISSE（福他替尼二鈉六水合物）片劑，這是一種經批准的口服脾酪氨酸激酶抑制劑，用於治療對先前治療反應不足的慢性免疫性血小板減少症 (ITP) 成人患者。其第二款產品是 REZLIDHIA（奧魯他尼）膠囊，用於治療經 FDA 批准的檢測檢測出易感異檸檬酸脫氫酶-1 (IDH1) 突變的復發或難治性 (R/R) 急性髓細胞白血病 (AML) 成人患者。其產品 GAVRETO（pralsetinib）是一種每日一次的小分子口服激酶抑制劑，用於抑制轉染過程中重排的野生型 RET 和致癌 RET 融合。

Rigel Pharmaceuticals Inc簡介



公司代碼RIGL

公司名稱Rigel Pharmaceuticals Inc

上市日期Nov 29, 2000

CEOMr. Raul R. Rodriguez

員工數量162

證券類型Ordinary Share

年結日Nov 29

公司地址- -

城市- -

上市交易所NASDAQ Global Select Consolidated

國家- -

郵編- -

電話- -

網址- -

公司代碼RIGL

上市日期Nov 29, 2000

CEOMr. Raul R. Rodriguez

Rigel Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Raul R. Rodriguez

President, Chief Executive Officer, Director

239.45K

-3.76%

Mr. Dean L. Schorno, CPA

Chief Financial Officer, Executive Vice President

57.23K

-6.18%

Mr. David A. Santos

Executive Vice President, Chief Commercial Officer

51.70K

-7.05%

Dr. Lisa Rojkjaer, M.D.

Executive Vice President, Chief Medical Officer

19.72K

--

Dr. Walter H. Moos, Ph.D.

Independent Director

12.72K

+24.46%

Ms. Jane Wasman, J.D.

Independent Director

12.50K

+25.00%

Ms. Kamil Ali-Jackson, Esq., J.D.

Independent Director

9.38K

+36.36%

Mr. Gregg A. Lapointe, CPA

Independent Chairman of the Board

--

Dr. Alison L. Hannah, M.D.

Independent Director

--

Mr. Raymond J. Furey

Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Raul R. Rodriguez

President, Chief Executive Officer, Director

239.45K

-3.76%

Mr. Dean L. Schorno, CPA

Chief Financial Officer, Executive Vice President

57.23K

-6.18%

Mr. David A. Santos

Executive Vice President, Chief Commercial Officer

51.70K

-7.05%

Dr. Lisa Rojkjaer, M.D.

Executive Vice President, Chief Medical Officer

19.72K

--

Dr. Walter H. Moos, Ph.D.

Independent Director

12.72K

+24.46%

Ms. Jane Wasman, J.D.

Independent Director

12.50K

+25.00%

收入明細

暫無數據

暫無數據

業務

地區

暫無數據

股東統計

更新時間: 10月14日週二

持股股東

股東類型

持股股東

佔比

Armistice Capital LLC

8.81%

Morgan Stanley & Co. LLC

8.15%

BlackRock Institutional Trust Company, N.A.

7.75%

The Vanguard Group, Inc.

5.75%

Soleus Capital Management, L.P.

3.63%

其他

65.91%

持股股東

佔比

Armistice Capital LLC

8.81%

Morgan Stanley & Co. LLC

8.15%

BlackRock Institutional Trust Company, N.A.

7.75%

The Vanguard Group, Inc.

5.75%

Soleus Capital Management, L.P.

3.63%

其他

65.91%

股東類型

持股股東

佔比

Investment Advisor

29.65%

Investment Advisor/Hedge Fund

23.66%

Hedge Fund

16.09%

Research Firm

10.33%

Individual Investor

2.62%

Pension Fund

0.69%

Bank and Trust

0.13%

Insurance Company

0.03%

其他

16.78%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

291

14.62M

80.57%

-798.43K

2025Q2

290

14.23M

79.32%

-22.43K

2025Q1

295

14.90M

83.36%

+888.64K

2024Q4

281

12.77M

72.51%

-849.60K

2024Q3

291

12.41M

70.53%

-421.54K

2024Q2

303

10.88M

61.98%

-2.99M

2024Q1

319

11.57M

65.99%

-3.84M

2023Q4

326

11.03M

63.24%

-4.70M

2023Q3

343

11.50M

66.01%

-5.45M

2023Q2

356

11.96M

68.88%

-4.98M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Armistice Capital LLC

1.60M

8.92%

+84.00K

+5.54%

Jun 30, 2025

Morgan Stanley & Co. LLC

1.48M

8.25%

-986.00

-0.07%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

1.41M

7.85%

-63.90K

-4.34%

Jun 30, 2025

The Vanguard Group, Inc.

1.05M

5.87%

+24.80K

+2.41%

Jun 30, 2025

Soleus Capital Management, L.P.

658.14K

3.67%

-472.53K

-41.79%

Jun 30, 2025

Acadian Asset Management LLC

623.00K

3.47%

+57.96K

+10.26%

Jun 30, 2025

State Street Investment Management (US)

600.18K

3.35%

-36.85K

-5.79%

Jun 30, 2025

Capitolis Liquid Global Markets LLC

591.55K

3.3%

-101.55K

-14.65%

Jun 30, 2025

Geode Capital Management, L.L.C.

415.61K

2.32%

+4.44K

+1.08%

Jun 30, 2025

Marshall Wace LLP

368.95K

2.06%

+157.20K

+74.24%

Jun 30, 2025

持股ETF



更新時間: 11月6日週四

機構名稱

佔比

iShares Genomics Immunology and Healthcare ETF

1.11%

Zacks Small/Mid Cap ETF

0.81%

Inspire Fidelis Multi Factor ETF

0.81%

Janus Henderson Small/Mid Cap Growth Alpha ETF

0.81%

First Trust Dow Jones Select MicroCap Index Fund

0.79%

Janus Henderson Small Cap Growth Alpha ETF

0.64%

ALPS Medical Breakthroughs ETF

0.29%

ALPS Barron's 400 ETF

0.19%

First Trust Active Factor Small Cap ETF

0.13%

JPMorgan Diversified Return U.S. Small Cap Equity ETF

0.13%

iShares Genomics Immunology and Healthcare ETF

佔比1.11%

Zacks Small/Mid Cap ETF

佔比0.81%

Inspire Fidelis Multi Factor ETF

佔比0.81%

Janus Henderson Small/Mid Cap Growth Alpha ETF

佔比0.81%

First Trust Dow Jones Select MicroCap Index Fund

佔比0.79%

Janus Henderson Small Cap Growth Alpha ETF

佔比0.64%

ALPS Medical Breakthroughs ETF

佔比0.29%

ALPS Barron's 400 ETF

佔比0.19%

First Trust Active Factor Small Cap ETF

佔比0.13%

JPMorgan Diversified Return U.S. Small Cap Equity ETF

佔比0.13%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Jun 25, 2024

Merger

10→1

Jun 25, 2024

Merger

10→1

Jun 25, 2024

Merger

10→1

Jun 25, 2024

Merger

10→1

公告日期

類型

比率

Jun 25, 2024

Merger

10→1

Jun 25, 2024

Merger

10→1

Jun 25, 2024

Merger

10→1

Jun 25, 2024

Merger

10→1